These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2854601)

  • 21. Protection from lethal herpes simplex virus type 1 infection by vaccination with a UL41-deficient recombinant strain.
    Koshizuka T; Ishioka K; Kobayashi T; Ikuta K; Suzutani T
    Fukushima J Med Sci; 2016 Jun; 62(1):36-42. PubMed ID: 26983589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of a US3 lacZ insertion mutant of herpes simplex virus type 2 and characterization of its phenotype in vitro and in vivo.
    Nishiyama Y; Yamada Y; Kurachi R; Daikoku T
    Virology; 1992 Sep; 190(1):256-68. PubMed ID: 1326804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus.
    Irie H; Shimeld C; Williams N; Hill T
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1357-62. PubMed ID: 8393076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice.
    Walker J; Laycock KA; Pepose JS; Leib DA
    Vaccine; 1998 Jan; 16(1):6-8. PubMed ID: 9607002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological basis for virulence of three strains of herpes simplex virus type 1.
    Sedarati F; Stevens JG
    J Gen Virol; 1987 Sep; 68 ( Pt 9)():2389-95. PubMed ID: 2821178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A herpes simplex virus type 1 mutant containing a deletion within immediate early gene 1 is latency-competent in mice.
    Clements GB; Stow ND
    J Gen Virol; 1989 Sep; 70 ( Pt 9)():2501-6. PubMed ID: 2550578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence.
    MacLean AR; ul-Fareed M; Robertson L; Harland J; Brown SM
    J Gen Virol; 1991 Mar; 72 ( Pt 3)():631-9. PubMed ID: 1848598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of genital herpes simplex virus infection in mice. III. Comparison of the virulence of wild and mutant strains.
    Schneweis KE; Forstbauer H; Olbrich M; Tag M
    Med Microbiol Immunol; 1984; 173(4):187-96. PubMed ID: 6096684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multigenic control of virus virulence in intertypic recombinants of herpes simplex virus.
    Batra SK; Brown SM
    Indian J Exp Biol; 1990 Oct; 28(10):960-3. PubMed ID: 2177726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSV-1 thymidine kinase negative vaccine: pathogenicity, protection, and perils.
    Gordon YJ; Lance S; Ricardi T; Romanowski E; Araullo-Cruz T
    Curr Eye Res; 1987 Jan; 6(1):151-9. PubMed ID: 3030639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.
    Asher LV; Walz MA; Notkins AL
    Am J Obstet Gynecol; 1978 Aug; 131(7):788-91. PubMed ID: 210669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.
    Scriba M
    Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex viruses: is a vaccine tenable?
    Whitley RJ; Roizman B
    J Clin Invest; 2002 Jul; 110(2):145-51. PubMed ID: 12122103
    [No Abstract]   [Full Text] [Related]  

  • 35. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type 1 variant 1716.
    Robertson LM; MacLean AR; Brown SM
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():967-70. PubMed ID: 1321881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurovirulent strains of herpes simplex virus type 1 are not necessarily competent for reactivatable latency.
    Arao Y; Hatano A; Yamada M; Uno F; Nii S
    Acta Med Okayama; 1991 Apr; 45(2):117-21. PubMed ID: 1651044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine.
    Irie H; Harada Y; Kataoka M; Nagamuta M; Moriya Y; Handa M; Saito M; Matsubara S; Kojima K; Sugawara Y
    J Virol; 1992 Apr; 66(4):2428-34. PubMed ID: 1312638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells.
    Ghasemi M; Erturk M; Buruk K; Sonmez M
    Cytotherapy; 2013 Mar; 15(3):352-61. PubMed ID: 23579060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes simplex virus vaccines--where are we?
    Kit S; Kit M
    Clin Obstet Gynecol; 1985 Mar; 28(1):164-77. PubMed ID: 2985314
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.